Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSLCSLLY -0.59%63 Price-to-Tangible-Book is 15.12 as of Aug. 23, 2026, which is 26% below its 10-year median of 20.50. GuruFocus rates CSLLY with a GF Score™ of 63/100 and a GF Value™ of $47.43 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 1,128 Biotechnology companies, CSL ranks worse than 89.1% on this metric.
As of today (2026-08-23), CSL's share price is $30.26. CSL's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was $2.00. Hence, CSL's Price to Tangible Book Ratio of today is 15.12.
The historical rank and industry rank for CSL's Price-to-Tangible-Book or its related term are showing as below:
CSLLY'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.63 Med: 20.5 Max: 93.16
Current: 14.76
During the past 13 years, CSL's highest Price to Tangible Book Ratio was 93.16. The lowest was 7.63. And the median was 20.50.
CSLLY's Price-to-Tangible-Book is ranked worse than 89.1% of 1128
companies
in the Biotechnology industry
Industry Median: 3.275
vs CSLLY: 14.76
A closely related ratio is called PB Ratio. As of today, CSL's share price is $30.26. CSL's Book Value per Sharefor the quarter that ended in Jun. 2026 was $7.72. Hence, CSL's P/B Ratio of today is 3.92.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
CSL Price-to-Tangible-Book Related Terms
CSL Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for CSL's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, RVMD: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, CSL's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where CSL's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
CSL (CSLLY) has a Price-to-Tangible-Book of 15.12 as of Aug. 23, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on CSL and its competitors. This is 26% below median its historical median of 20.50. Over the past decade, CSL's Price-to-Tangible-Book has ranged from 7.63 to 93.16. According to the industry distribution chart, CSL ranks #1005 out of 1128 companies in the Biotechnology industry, placing it in the top 89.1%.
Is CSL's Price-to-Tangible-Book too high?
CSL's current Price-to-Tangible-Book of 15.12 is 26% below median its 10-year median of 20.50. Over the past 10 years, this metric has ranged from a low of 7.63 to a high of 93.16. The Biotechnology industry median Price-to-Tangible-Book is 3.28. CSL's value of 15.12 is 361.7% above this industry median. Based on the distribution chart, CSL ranks #1005 out of 1128 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #1005 out of 1128 companies for Price-to-Tangible-Book. This places CSL in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.28. CSL's value of 15.12 is 361.7% above this benchmark. Historically, CSL's own Price-to-Tangible-Book has ranged from 7.63 to 93.16 over the past decade. While the company's 10-year median is 20.50 vs. the industry median of 3.28, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.28, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Price-to-Tangible-Book of 15.12 is 361.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on CSL and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Price-to-Tangible-Book is 15.12, which is 26% below median its own 10-year median of 20.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.43, compared to a current price of $30.26 — trading 36.2% below its estimated fair value. The current Price-to-Tangible-Book is 15.12, which is 26% below median its 10-year median of 20.50 and 361.7% above the Biotechnology industry median of 3.28. CSL's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For CSL (CSLLY), the current Price-to-Tangible-Book is 15.12 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $30.26 is trading 36.2% below its estimated GF Value™ of $47.43.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Price-to-Tangible-Book: 15.12 (26% below median its 10-year median of 20.50)
GF Value™: $47.43 vs. price of $30.26 (36.2% below fair value)
Industry Position: 361.7% above the Biotechnology median (#1005 of 1128)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
63GF Score
Get the complete analysis for CSLLY
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
